Clinical and biological features of t(4;14) multiple myeloma: a prospective study

Item

http://www.wikidata.org/entity/Q57217664

description

im Januar 2011 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 24 January 2011

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2011

@uk

name

Clinical and biological features of t

@nl

Clinical and biological features of t(4;14) multiple myeloma: a prospective study

@en

type

Item

label

Clinical and biological features of t

@nl

Clinical and biological features of t(4;14) multiple myeloma: a prospective study

@en

prefLabel

Clinical and biological features of t

@nl

Clinical and biological features of t(4;14) multiple myeloma: a prospective study

@en

P1476

Clinical and biological features of t(4;14) multiple myeloma: a prospective study

@en

P2093

Bertrand Arnulf

http://www.w3.org/2001/XMLSchema#string

Bouchra Asli

http://www.w3.org/2001/XMLSchema#string

David Ghez

http://www.w3.org/2001/XMLSchema#string

Jean Christophe Bories

http://www.w3.org/2001/XMLSchema#string

Jean Claude Brouet

http://www.w3.org/2001/XMLSchema#string

Jean Paul Fermand

http://www.w3.org/2001/XMLSchema#string

Jean Soulier

http://www.w3.org/2001/XMLSchema#string

Karim Belhadj

http://www.w3.org/2001/XMLSchema#string

Lionel Karlin

http://www.w3.org/2001/XMLSchema#string

Margaret Macro

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.

International uniform response criteria for multiple myeloma.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

Do beta2 microglobulin levels affect survival of newly diagnosed myeloma patients with translocation t(4;14) or 17p13 deletion treated with conventional chemotherapy?

CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

P304

238-246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2010.537795

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olivier Hermine

Raphaël Porcher

Didier Bouscary

P577

2011-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21261498

http://www.w3.org/2001/XMLSchema#string